Merger of Neoleukin Therapeutics, Inc. and Aquinox Pharmaceuticals, Inc. - Schedule of Total Consideration Paid (Detail) $ in Thousands	Aug. 08, 2019 USD ($)
Acquisition Of Assets [Line Items]
Cash consideration for fractional shares	$ 5
Transaction costs	3,087
Total consideration	51,578
Aquinox [Member] | Common Stock [Member]
Acquisition Of Assets [Line Items]
Fair Value	15,054
Convertible Preferred Stock [Member] | Aquinox [Member]
Acquisition Of Assets [Line Items]
Fair Value	$ 33,432